Iain Simpson Selected Research

AZD-0364

1/2021	AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib.
12/2019	Discovery of a Potent and Selective Oral Inhibitor of ERK1/2 (AZD0364) That Is Efficacious in Both Monotherapy and Combination Therapy in Models of Nonsmall Cell Lung Cancer (NSCLC).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Iain Simpson Research Topics

Disease

2	Neoplasms (Cancer) 01/2021 - 12/2017
1	Autoimmune Diseases (Autoimmune Disease) 01/2020
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/2019
1	Melanoma (Melanoma, Malignant) 12/2019
1	Chronic Progressive Multiple Sclerosis 01/2019
1	Human Influenza (Influenza) 01/2019
1	Multiple Sclerosis 01/2019
1	Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker) 01/2018
1	Dry Eye Syndromes (Dry Eye Syndrome) 01/2018
1	Chronic Obstructive Pulmonary Disease (COPD) 01/2018
1	Peripheral Arterial Disease 01/2018
1	Progressive Supranuclear Palsy (Steele Richardson Olszewski Syndrome) 07/2017
1	Pulmonary Hypertension 07/2017
1	Alzheimer Disease (Alzheimer's Disease) 02/2017
1	Lung Neoplasms (Lung Cancer) 02/2017
1	Rheumatoid Arthritis 02/2017
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/2016
1	Out-of-Hospital Cardiac Arrest 05/2016
1	Hypertension (High Blood Pressure) 01/2015
1	Inflammation (Inflammations) 10/2011
1	Coronary Artery Disease (Coronary Atherosclerosis) 06/2003
1	Atherosclerosis 06/2003

Drug/Important Bio-Agent (IBA)

5	Pharmaceutical PreparationsIBA 01/2019 - 01/2015
3	Biomarkers (Surrogate Marker)IBA 01/2021 - 10/2011
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2021 - 12/2019
2	AZD-0364IBA 01/2021 - 12/2019
1	AZD 6244IBA 01/2021
1	EnzymesIBA 01/2020
1	Syk KinaseIBA 01/2020
1	Antiviral Agents (Antivirals)IBA 01/2019
1	siponimodIBA 01/2019
1	ocrelizumabIBA 01/2019
1	Oncogene Proteins (Oncogene Protein)IBA 12/2017
1	Tumor Biomarkers (Tumor Markers)IBA 02/2017
1	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 12/2016
1	Antihypertensive Agents (Antihypertensives)IBA 01/2015
1	salicylhydroxamic acid (SHAM)IBA 01/2015
1	Arachidonic Acid (Vitamin F)IBA 10/2011
1	C-Reactive ProteinIBA 10/2011
1	Interleukin-6 (Interleukin 6)IBA 10/2011
1	Adenosine Diphosphate (ADP)IBA 10/2011
1	CD40 Ligand (CD40L)IBA 10/2011
1	Clopidogrel (Plavix)FDA Link 10/2011
1	ApolipoproteinsIBA 06/2003
1	Apolipoproteins E (ApoE)IBA 06/2003

Therapy/Procedure

3	Therapeutics 12/2019 - 01/2015
2	Nebulizers and Vaporizers (Inhaler) 07/2017 - 02/2017
1	Vascular Surgical Procedures 01/2018
1	Resuscitation 05/2016
1	Denervation 01/2015